Tolerability of Peg interferon-α2b and Ribavirin therapy in patients with chronic hepatitis C and glucose-6-phosphate dehydrogenase deficiency

Journal of Hepatology

Volumn 46, Issue 1, 2007, Pages 171-173

  Demelia, Luigi ^a   Civolani, Alberto ^a   Murgia, Debora ^a   Murru, Alessandra ^a   Sorbello, Orazio ^a   Rizzetto, Mario ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; HEMOGLOBIN; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANEMIA; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DEMOGRAPHY; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; GENOTYPE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEALTH SURVEY; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINURIA; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; JAUNDICE; LETTER; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RETICULOCYTE COUNT; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TREATMENT DURATION; VIROLOGY;

ADULT; ANEMIA, HEMOLYTIC; ANTIVIRAL AGENTS; DRUG TOLERANCE; FEMALE; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN;

EID: 37849187255     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.10.003     Document Type: Letter

References (11)

1. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., and Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
2. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., and Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
3. Sulkowski M.S., Wasserman R., Brooks L., Ball L., and Gish R. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 11 (2004) 243-250
4. Jaap S., and Martin P. Hemolytic anemia and the treatment of chronic hepatitis C. J Clin Gastroenterol 28 (1999) 289-290
5. Grattagliano I., Russmann S., Palmieri V.O., Juni P., Bihl F., Portincasa P., Palasciano G., and Lauterburg B.H. Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C. Hepatology 39 (2004) 1248-1255
6. Balestrieri C., Serra G., Cauli C., Chessa L., Balestrieri A., and Farci P. Treatment of chronic hepatitis C in patients with Glucose-6-phosphate dehydrogenase deficiency: is Ribavirin harmful?. Blood 107 (2006) 3409-3410
7. Bini E.J., Anand B.S., Samanta A., Cordoba-Rellosa I., Nemchausky B., Trevino H.H., Weston A.P., Pimstone N.R., Stancic S., and Chang K.M. Glucose-6-phosphate dehydrogenase deficiency is associated with severe anemia during interferon and ribavirin therapy. AASLD (2005) 1151
8. Carcassi U.E.F. The interaction between thalassemia, G6PD deficiency and favism. Ann N Y Acad Sci USA 232 (1974) 297-305
9. Coppola R.C., Masia G., Pradat P., Trepò C., Carboni G., Argiolas F., and Rizzetto M. Impact of hepatitis C virus infection on healthy subjects on an Italian island. J Viral Hepat 7 (2000) 130-137
10. WHO Technical Report Series No. 366, 1967, Standardization of Procedures for the Study of Glucose-6-Phosphate Deydrogenase.
11. Hadziyannis S.J., Sette Jr. H., and Morgan T.R. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355